HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7

Benzinga · 1d ago
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $15 to $7.